UCSF School of Medicine
T

ASCO 2021 Updates on EV-103: Durability Results and Long-Term Outcome of Enfortumab Vedotin + Pembro in 1L la/mUC

By UCSF School of Medicine FEATURING Terence Friedlander
By UCSF School of Medicine FEATURING Terence Friedlander
443 views
June 15, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

19:47
Janssen Oncology

All Things PSA

Feat. J. Hamilton, M. Fabrizio, M. Taha

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Related Content

AUTOPLAY
16:05
Insights from 2024 ASCO® GU Annual Meeting

Recent GU Developments and Their Clinical Implications

Feat. T. Powles, B. Rini
15:58
Total Health

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Feat. M. Reimers
22:19
Insights from 2023 ESMO Annual Meeting

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Feat. G. Sonpavde
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
14:00
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Ca…

Feat. G. Sonpavde
06:01
ecancer

ESMO 2023 Insights: "Phase 3 EV-302 Trial - Evaluating the Comb…

Feat. T. Powles
17:32
Kriti Mittal

Current Updates in Urothelial Cancer: Clinical Implications for Prac…

19:30
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

Sequencing 1L Therapies in Metastatic Urothelial Carcinoma

Feat. P. Grivas
30:03
UCSF School of Medicine

Recent Advances in Advanced Urothelial Cancers: Time for a New Stand…

Feat. T. Friedlander
11:29
Oncology Data Advisor

Enfortumab Vedotin + Pembro for Previously Untreated Advanced Urothe…

Feat. T. Powles
13:54
AdventHealth

FDA Approval of Gemcitabine-Cisplatin + Nivo as 1L Therapy for Advan…

Feat. G. Sonpavde
09:12
AdventHealth

Update on the FDA Accelerated Approval of Enfortumab Vedotin + Pembr…

Feat. G. Sonpavde
05:59
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "EV-302/KEYNOTE-A39 Study of Enfortumab Ved…

Feat. T. Powles
15:50
Petros Grivas

Year in Review: Bladder Cancer

28:53
OncoAlert

Year in Review: Best of Bladder Cancer Updates in 2023

Feat. A. Apolo
17:03
Total Health

Emerging Trends in Localized Bladder Cancer in 2024

Feat. N. Gopal
12:54
Scripps MD Anderson Cancer Center

Recent Advances in Therapy for Bladder Cancer

Feat. M. Bhangoo
05:48
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Insights: "UNITE Study - Outcomes in Patients Wit…

Feat. A. Nizam
10:27
Robert McBane

2023 ISTH Insights: "The EVE Trial - Extending VTE Secondary Pr…

09:22
ASCO GU 2023 Conference Coverage

ASCO GU 2023: Dr. Park and Dr. Grivas Discuss TROPHY-U-01 and EV-201…

Feat. P. Grivas, C. Park